欧州連合 - スロベニア語 - EMA (European Medicines Agency)

wyeth europa ltd - gemtuzumab ozogamicin - leukemija, myeloid, akutna - antineoplastična sredstva - ponovno indukcijsko zdravljenje cd33-pozitivno aml odraslih bolnikih v prvi ponovitve, ki niso kandidati za druge intenzivno ponovno indukcijske kemoterapijo regimens (e. visoki odmerki ara-c) in ki izpolnjujejo vsaj enega od naslednjih kriterijev: trajanje prvi odpust 60 let.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - cepiva - aktivne imunizacije proti bolezni, ki povzroča streptococcus pneumoniae serotipe 4, 6b, iz 9v, 14, 18 c, 19f in 23f (vključno s sepso, meningitisom, pljučnica, bakteriemija in akutni otitis media) pri dojenčkih in otrocih od dveh mesecev do petih let starosti. uporaba prevenar je treba določiti na podlagi uradnih priporočil, ob upoštevanju vpliva invazivnih bolezni v različnih starostnih skupin, kot tudi variabilnost serotip epidemiologija v različnih geografskih področjih,.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.

スロベニア - スロベニア語 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer europe ma, eeig - piperacilin; tazobaktam - prašek za raztopino za infundiranje - piperacilin 4 g / 1 viala  tazobaktam0,5 g / 1 viala; tazobaktam 0,5 g / 1 viala - piperacilin in zaviralec laktamaz beta

スロベニア - スロベニア語 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

pfizer europe ma, eeig - piperacilin, tazobaktam - prašek za raztopino za infundiranje - piperacilin 4 g / 1 viala; tazobaktam 0,5 g / 1 viala - piperacilin in zaviralec laktamaz beta

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer limited  - metaflumizon - ectoparasiticides za lokalno uporabo, vključno. insekticidi - mačke - zdravljenje in preprečevanje bolh infestations (ctenocephalides canis in c. felis) pri mačkah. zdravilo za uporabo v veterinarski medicini se lahko uporablja kot del strategije zdravljenja alergijskega dermatitisa bolh (fad).

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer limited  - metaflumizone, amitraz - ectoparasiticides za lokalno uporabo, vključno. insekticidi - psi - za zdravljenje in preprečevanje infestacij z bolhami (ctenocephalides canis in c. felis) in klopi (ixodes ricinus, ixodes hexagonus, rhipicephalus sanguineus, dermacentor reticulatus in dermacentor variabilis), zdravljenje demodicosis (zaradi demodex spp. ) in uši (trichodectes canis) pri psih. zdravilo za uporabo v veterinarski medicini se lahko uporablja kot del strategije zdravljenja alergijskega dermatitisa bolh (fad).

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibacterials za sistemsko uporabo, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: , complicated skin and soft tissue infections (cssti), excluding diabetic foot infections, complicated intra-abdominal infections (ciai) , tygacil should be used only in situations where other alternative antibiotics are not suitable. upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti. ustrezno uporabo protibakterijsko agenti.

欧州連合 - スロベニア語 - EMA (European Medicines Agency)

astrazeneca ab - eksenatid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - byetta je indiciran za zdravljenje tipa 2 sladkorna bolezen v kombinaciji z:metformin;sulphonylureas;thiazolidinediones;metforminom in sulfonil sečnine;metforminom in thiazolidinedione;pri odraslih, ki niso dosegli ustreznega glycaemic nadzor na maksimalno dopustne koncentracije teh ustni terapije. byetta je prikazano tudi kot adjunctive terapija za bazalni insulin z ali brez metforminom in / ali pioglitazone pri odraslih, ki niso dosegli ustreznega glycaemic nadzor s temi zdravili.

スロベニア - スロベニア語 - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

octapharma (ip) ltd., - plazemski proteini, humani - raztopina za infundiranje - plazemski proteini, humani 70 µg / 1 ml - nadomestki krvi in plazemske proteinske frakcije